Short Interest in ERYTECH Pharma S.A. (NASDAQ:ERYP) Decreases By 15.9%

ERYTECH Pharma S.A. (NASDAQ:ERYPGet Rating) was the recipient of a significant decrease in short interest in May. As of May 31st, there was short interest totalling 81,200 shares, a decrease of 15.9% from the May 15th total of 96,500 shares. Based on an average daily volume of 907,900 shares, the short-interest ratio is currently 0.1 days.

A hedge fund recently bought a new stake in ERYTECH Pharma stock. Citadel Advisors LLC purchased a new stake in shares of ERYTECH Pharma S.A. (NASDAQ:ERYPGet Rating) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,565 shares of the company’s stock, valued at approximately $84,000. Citadel Advisors LLC owned about 0.05% of ERYTECH Pharma at the end of the most recent reporting period. 30.13% of the stock is owned by hedge funds and other institutional investors.

ERYTECH Pharma stock opened at $1.07 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.00 and a quick ratio of 2.00. ERYTECH Pharma has a fifty-two week low of $1.00 and a fifty-two week high of $9.50. The firm has a fifty day moving average price of $1.22 and a two-hundred day moving average price of $1.74.

ERYTECH Pharma Company Profile (Get Rating)

ERYTECH Pharma SA, a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for ERYTECH Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ERYTECH Pharma and related companies with MarketBeat.com's FREE daily email newsletter.